Semaglutide
Also known as: Semaglutide (GLP-1 agonist)
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.
Who's worth your money for Semaglutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (95) of 7 scored sellers
$70.00 · 15mg · 99.2% purity
Best value
Lowest $/mg among scored sellers
$10.00 · 10mg
Most tested
11 independent COAs on file
$90.00 · 10mg · 99.9% purity
Average price
$9.02/mg
Sellers
63
45-day trend
+12.6%
55 of 63 sellers have a current price· 48 stale hidden
Top Merit pick
🇺🇸 Prime Peptides95✓ verified at source · just now
$4.67/mg -48.3% vs avg$70.00
15mg
- 🇺🇸 Polaris Peptides90
✓ verified at source · just now
$9.00/mg -0.2% vs avg$90.00
10mg
- 🇨🇳 Reta Peptide83
✓ verified at source · just now
$6.50/mg -28% vs avg$65.00
10mg
- 🇺🇸 Blank Peptides81
✓ verified at source · just now
$7.90/mg -12.4% vs avg$79.00
10mg
- 🇺🇸 Bulk Peptides50
✓ verified at source · just now
$16.00/mg +77.3% vs avg$160
10mg
- 🇭🇰 Hkuppeptide49
✓ verified at source · just now
$1.00/mg -88.9% vs avg$10.00
10mg
no purity - 🇭🇰 zztai Peptide Ltd42
✓ verified at source · just now
$3.87/mg -57.1% vs avg$116
30mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Semaglutide
Get one email when the market actually moves — no newsletter, no noise.
About Semaglutide
CAS
910463-68-2
Molecular formula
C187H291N45O59
Typical dose range
0.25–2.4 mg (250–2400 mcg) subcutaneous once weekly; typically titrated from 0.25 mg/week, increasing every 4 weeks
Half-life
~7 days
COAs for Semaglutide
185 third-party tests across 28 vendors. Each card links to the full report.
For
Semaglutide
by Peptide Plugs· batch 189-02-DK
For
Semaglutide
by Hydro Research Peptides· batch HR-2026-7341
For
Semaglutide
by Longeva· batch B-2026-SEMA-5-001
For
Semaglutide
by Peptide Partners· batch SPL-4149
For
Semaglutide
by Peptide Plugs· batch 125-01-SM
For
Semaglutide
by Soma Peptides· batch SEV052657
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by Blank Peptides· batch GS10-052026-4
For
Semaglutide
by Pepsgpt· batch P-2885342-P
For
Semaglutide
by Prime Peptides· batch 3022026SM
For
Semaglutide
by Prime Peptides· batch 3142026SM
For
Semaglutide
by Prime Peptides· batch 2242026SM
For
ION-1S
by Ion Peptide· batch ION1S20-04172026
For
Semaglutide
by Vertex Labs· batch SM0000038
For
Semaglutide
by OROS Research· batch OR-LPGLPS10-426-B3
For
Semaglutide
by Prime Peptides· batch 3272026SM
For
Semaglutide
by Prime Peptides· batch 3222026SX
For
Semaglutide
by Blank Peptides· batch 665394
For
Semaglutide
by Prime Peptides· batch 2182026SM
For
Semaglutide
by Prime Peptides· batch 2122026SM
For
Semaglutide
by Orbitrex Peptides· batch 1G200426
For
Semaglutide
by Qihang Peptide· batch 3
For
Semaglutide
by Peptide Crafters· batch PC-G2-S10
23 citations indexed for Semaglutide
meta-analysis · 2026
Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, are widely used for Type 2 diabetes mellitus (T2DM), obesity and related metabolic conditions. Evidence on potential neuropsychiatric effects remains inconsistent.
animal · 2026
Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice
Obesity is a major contributor to cardiometabolic disease, and pharmacological therapies, such as semaglutide, are increasingly used to induce weight loss.
review · 2026
Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis
Background/objectives Obesity is a chronic, relapsing disease associated with multiple serious comorbidities. Semaglutide has emerged as an effective pharmacological option for obesity management, owing to its substantial effects on weight loss, cardiometabolic risk factors, and patient-reported outcomes.
cohort · 2026
Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice
Introduction Glucagon-like peptide-1 receptor agonists are effective glucose-lowering agents with established benefits on body weight and cardiometabolic outcomes.
Study · 2026
Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial
Background This subgroup analysis assessed the efficacy and safety of semaglutide in the Japanese subgroup versus the overall trial population of ESSENCE (part 1) and evaluated the impact of baseline characteristics.
Study · 2026
Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study
Background Endoscopic sleeve gastroplasty (ESG) and semaglutide are established therapies for obesity. However, comparative real-world data remain limited. We compared the effectiveness and safety of ESG versus oral semaglutide 14 mg in adults with obesity.